-
Je něco špatně v tomto záznamu ?
Adenosine A1 Receptor Agonist 2-chloro-N6-cyclopentyladenosine and Hippocampal Excitability During Brain Development in Rats
P. Fabera, M. Parizkova, L. Uttl, K. Vondrakova, H. Kubova, G. Tsenov, P. Mares,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
31258477
DOI
10.3389/fphar.2019.00656
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Objective: The adenosinergic system may influence excitability in the brain. Endogenous and exogenous adenosine has anticonvulsant activity presumably by activating A1 receptors. Adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) may thus bolster anticonvulsant effects, but its action and the number of A1 receptors at different developmental stages are not known. Methods: Hippocampal epileptic afterdischarges (ADs) were elicited in 12-, 15-, 18-, 25-, 45-, and 60-day-old rats. Stimulation and recording electrodes were implanted into the dorsal hippocampus. The A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 0.5 or 1 mg/kg) was administered intraperitoneally 10 min before the first stimulation. Control animals were injected with saline. All rats were stimulated with a 2-s series of 1-ms biphasic pulses delivered at 60 Hz with increasing stepwise intensity (0.05-0.6 mA). Each age and dose group contained 9-14 animals. The AD thresholds and durations were evaluated, and the A1 receptors were detected in the hippocampus in 7-, 10-, 12-, 15-, 18-, 21-, 25-, 32-, and 52-day-old rats. Results: Both CCPA doses significantly increased hippocampal AD thresholds in 12-, 15-, 18-, and 60-day-old rats compared to controls. In contrast, the higher dose significantly decreased AD threshold in the 25-day-old rats. The AD durations were significantly shortened in all age groups except for 25-day-old rats where they were significantly prolonged. A1 receptor expression in the hippocampus was highest in 10-day-old rats and subsequently decreased. Significance: The adenosine A1 receptor agonist CCPA exhibited anticonvulsant activity at all developmental stages studied here except for 25-day-old rats. Age-related differences might be due to the development of presynaptic A1 receptors in the hippocampus.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19036003
- 003
- CZ-PrNML
- 005
- 20191011115242.0
- 007
- ta
- 008
- 191007s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2019.00656 $2 doi
- 035 __
- $a (PubMed)31258477
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Fabera, Petr $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Department of Neurology, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia.
- 245 10
- $a Adenosine A1 Receptor Agonist 2-chloro-N6-cyclopentyladenosine and Hippocampal Excitability During Brain Development in Rats / $c P. Fabera, M. Parizkova, L. Uttl, K. Vondrakova, H. Kubova, G. Tsenov, P. Mares,
- 520 9_
- $a Objective: The adenosinergic system may influence excitability in the brain. Endogenous and exogenous adenosine has anticonvulsant activity presumably by activating A1 receptors. Adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) may thus bolster anticonvulsant effects, but its action and the number of A1 receptors at different developmental stages are not known. Methods: Hippocampal epileptic afterdischarges (ADs) were elicited in 12-, 15-, 18-, 25-, 45-, and 60-day-old rats. Stimulation and recording electrodes were implanted into the dorsal hippocampus. The A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 0.5 or 1 mg/kg) was administered intraperitoneally 10 min before the first stimulation. Control animals were injected with saline. All rats were stimulated with a 2-s series of 1-ms biphasic pulses delivered at 60 Hz with increasing stepwise intensity (0.05-0.6 mA). Each age and dose group contained 9-14 animals. The AD thresholds and durations were evaluated, and the A1 receptors were detected in the hippocampus in 7-, 10-, 12-, 15-, 18-, 21-, 25-, 32-, and 52-day-old rats. Results: Both CCPA doses significantly increased hippocampal AD thresholds in 12-, 15-, 18-, and 60-day-old rats compared to controls. In contrast, the higher dose significantly decreased AD threshold in the 25-day-old rats. The AD durations were significantly shortened in all age groups except for 25-day-old rats where they were significantly prolonged. A1 receptor expression in the hippocampus was highest in 10-day-old rats and subsequently decreased. Significance: The adenosine A1 receptor agonist CCPA exhibited anticonvulsant activity at all developmental stages studied here except for 25-day-old rats. Age-related differences might be due to the development of presynaptic A1 receptors in the hippocampus.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Parizkova, Martina $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Department of Neurology, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia.
- 700 1_
- $a Uttl, Libor $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. National Institute of Mental Health, Klecany, Czechia.
- 700 1_
- $a Vondrakova, Katerina $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. National Institute of Mental Health, Klecany, Czechia.
- 700 1_
- $a Kubova, Hana $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
- 700 1_
- $a Tsenov, Grygoriy $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
- 700 1_
- $a Mares, Pavel $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 10, č. - (2019), s. 656
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31258477 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191011115703 $b ABA008
- 999 __
- $a ind $b bmc $g 1452663 $s 1074553
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 10 $c - $d 656 $e 20190614 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20191007